Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 1/20 | 0.61 |
| ▸ | ACP1 | P24666 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973138 | 0.89 | CAMK2D (0.49) | CAMK2DACP1MEN1KMT2AMAPT | |
| SCHEMBL3975061 | 0.84 | TLR9 (0.52) | CAMK2DACP1MAPT | |
| SCHEMBL3976155 | 0.82 | KDM4E (0.52) | CAMK2DHTR3AMEN1KMT2AMAPT | |
| SCHEMBL3973406 | 0.80 | HTR3A (0.49) | CAMK2DACP1HTR3AMEN1KMT2A | |
| SCHEMBL3975320 | 0.80 | SLC2A1 (0.49) | ACP1HTR3AMEN1KMT2AMAPT | |
| SCHEMBL3980578 | 0.78 | MAPK1 (0.58) | ACP1HTR3AMEN1KMT2AMAPT | |
| SCHEMBL3974635 | 0.77 | ACP1 (0.58) | ACP1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL3977122 | 0.77 | HTR3A (0.58) | HTR3AMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL3981563 | 0.77 | HMOX1 (0.42) | CAMK2DACP1HTR3AMEN1KMT2A | |
| SCHEMBL3971156 | 0.76 | POLB (0.60) | ACP1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | CAMK2D 2629/4885ACP1 4097/4885HTR3A 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.